Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON: savolitinib + osimertinib versus platinum doublet chemotherapy after progression on osimertinib in EGFR-mutant, MET-positive advanced NSCLC
CTR20222068Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started May 2023; status: active.
02
Drugs
savolitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222068.